Implementation of a recombinant factor IX Fc fusion protein extended-infusion desensitization protocol

被引：4

作者：

Clough, A. M. ^{[1
]}

Gilreath, J. A. ^{[1
,2
]}

Mcpherson, J. . P. ^{[1
]}

Link, N. C. ^{[1
]}

Rodgers, G. M. ^{[3
]}

Nance, D. ^{[3
]}

机构：

[1] Huntsman Canc Inst, Dept Pharm, Salt Lake City, UT USA

[2] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA

[3] Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

来源：

HAEMOPHILIA | 2017年 / 23卷 / 03期

关键词：

HEMOPHILIA-B; ADVERSE-REACTIONS;

D O I：

10.1111/hae.13208

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E227 / E230

页数：5

共 10 条

[1] Modern haemophilia care [J].

Berntorp, Erik ;

Shapiro, Amy D. .

LANCET, 2012, 379 (9824) :1447-1456

[2]

Biogen Idec Inc, 2016, ALPR COAG FACT 9 REC, P1

[3] Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review [J].

Bon, Andrea ;

Morfini, Massimo ;

Dini, Alessandro ;

Mori, Francesca ;

Barni, Simona ;

Gianluca, Sottilotta ;

de Martino, Maurizio ;

Novembre, Elio .

ITALIAN JOURNAL OF PEDIATRICS, 2015, 41

[4] Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B [J].

Ducore, Jonathan M. ;

Miguelino, Maricel G. ;

Powell, Jerry S. .

EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) :559-571

[5] Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies [J].

Franchini, M. ;

Makris, M. ;

Santagostino, E. ;

Coppola, A. ;

Mannucci, P. M. .

HAEMOPHILIA, 2012, 18 (03) :e164-e172

[6] Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B [J].

Powell, Jerry S. ;

Pasi, K. John ;

Ragni, Margaret V. ;

Ozelo, Margareth C. ;

Valentino, Leonard A. ;

Mahlangu, Johnny N. ;

Josephson, Neil C. ;

Perry, David ;

Manco-Johnson, Marilyn J. ;

Apte, Shashikant ;

Baker, Ross I. ;

Chan, Godfrey C. ;

Novitzky, Nicolas ;

Wong, Raymond S. ;

Krassova, Snejana ;

Allen, Geoffrey ;

Jiang, Haiyan ;

Innes, Alison ;

Li, Shuanglian ;

Cristiano, Lynda M. ;

Goyal, Jaya ;

Sommer, Jurg M. ;

Dumont, Jennifer A. ;

Nugent, Karen ;

Vigliani, Gloria ;

Brennan, Aoife ;

Luk, Alvin ;

Pierce, Glenn F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24) :2313-2323

[7] A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B [J].

Recht, M. ;

Pollmann, H. ;

Tagliaferri, A. ;

Musso, R. ;

Janco, R. ;

Neuman, W. Richey .

HAEMOPHILIA, 2011, 17 (03) :494-499

[8] Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients [J].

Shapiro, Amy D. ;

Ragni, Margaret V. ;

Valentino, Leonard A. ;

Key, Nigel S. ;

Josephson, Neil C. ;

Powel, Jerry S. ;

Cheng, Gregory ;

Thompson, Arthur R. ;

Goyal, Jaya ;

Tubridy, Karen L. ;

Peters, Robert T. ;

Dumont, Jennifer A. ;

Euwart, Donald ;

Li, Lian ;

Hallen, Bengt ;

Gozzi, Peter ;

Bitonti, Alan J. ;

Jiang, Haiyan ;

Luk, Alvin ;

Pierce, Glenn F. .

BLOOD, 2012, 119 (03) :666-672

[9] Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates [J].

Shibata, M ;

Shima, M ;

Misu, H ;

Okimoto, Y ;

Giddings, JC ;

Yoshioka, A .

HAEMOPHILIA, 2003, 9 (03) :269-271

[10]

Wyeth BioPharma Division of Wyeth Pharmaceuticals Inc, 2015, BENEFIX COAG FACT 9, P1

← 1 →